SIG
ABBV icon

Stonegate Investment Group’s AbbVie ABBV Stock Holding History

Stonegate Investment Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,582
Closed -$266K – 326
2022
Q2 		$266K Buy
+1,582
New +$242K 0.01% 243

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stonegate Investment Group's ABBV Position: Q3 2025 in Review

Stonegate Investment Group increased its AbbVie (ABBV) stake by 0.55% in Q3 2025, buying an estimated $45.2K and bringing the position to 40,253 shares worth $9.32M. The position accounts for 0.22% of the portfolio, ranked #59.

Stonegate Investment Group first reported a position in ABBV in Q4 2021 and has held it in 16 quarters since. The position peaked at $62M in Q1 2023. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Stonegate Investment Group held 40,253 shares of AbbVie worth $9.32M as of Q3 2025.
  • Stonegate Investment Group bought 222 AbbVie shares in Q3 2025, an estimated $45.2K.
  • AbbVie made up 0.22% of Stonegate Investment Group's portfolio in Q3 2025, its #59 holding.
  • Stonegate Investment Group first reported a position in AbbVie in Q4 2021 and has held it in 16 quarters since.
  • Stonegate Investment Group's AbbVie position peaked at $62M in Q1 2023.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.